/CNW/ - Two new reports released by the Patented Medicine Prices Review Board (PMPRB) detail the current status of the market for new medicines in Canada,.
/CNW/ - The latest edition of the Patented Medicine Prices Review Board (PMPRB) Meds Entry Watch reports that 40 new-to-Canada medicines were approved for.
The latest edition of the Patented Medicine Prices Review Board (PMPRB) Meds Pipeline Monitor reports that oncology continued to dominate the therapeutic mix of the drug pipeline in 2020, with cancer treatments representing one third (35%) of medicines in all phases of clinical trials. Treatments for infectious diseases held the second largest share of the pipeline, at 13%, and are expected to grow in importance in response to the COVID-19 pandemic.
Meds Pipeline Monitor 2020 reviewed 935 new medicines in late stages of clinical evaluation to highlight drugs that could potentially impact the Canadian health care system. Among these, the PMPRB identified 16 late-stage new medicines, including five gene therapies, that may offer breakthroughs in treating previously unmet needs or have the potential to treat large patient populations, as well as six new medicines currently under review by Heath Canada. The report also provides an overview of the fast-moving pipeline for medicines and v
The latest edition of the Patented Medicine Prices Review Board (PMPRB) Meds Pipeline Monitor reports that oncology continued to dominate the therapeutic.